Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com’s coverage highlights our 3 biggest and most influential stories from the day’s news to make sure you’re up to date on the headlines that continue to shape the medical device industry.
Corindus Vascular Robotics priced its 11-million-share uplisting at $3.80 per share, saying it won approval to move its shares from the OTC exchange to the New York Stock Exchange effective today.
The offering is slated to gross $41.8 million, delivering proceeds before expenses of $39.3 million to Waltham, Mass.-based Corindus, which makes the CorPath robot-assisted surgery platform. Read more
2. Deals in hand, Zimmer ‘highly confident’ in June close for Biomet deal
With deals in hand to sell some U.S. knee and elbow assets to mollify anti-trust regulators, Zimmer said that it’s “highly confident” in a mid-June closing for its $13.34 billion merger with crosstown rival Biomet.
Warsaw, Ind.-based Zimmer said it found buyers for its unicompartmental High Flex knee implant and Biomet’s Discovery elbow device and Biomet’s Cobalt bone cement assets in the U.S. Read more
A Delaware state jury issued a $100 million judgment against Boston Scientific in a personal injury lawsuit filed over its Pinnacle and Advantage Fit pelvic mesh products, Bloomberg reported.
The jury found that the devices, used to treat pelvic organ prolapse and female urinary incontinence, were defectively designed and that company executives hid the flaws from plaintiff Deborah Barba, according to the news service. Read more